Navigation Links
FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Date:5/21/2009

sense or appropriately respond to thirst, hypovolemic hyponatremia, concomitant use of strong CYP 3A inhibitors, anuric patients

  • Too Rapid Correction of Serum Sodium Can Cause Serious Neurologic Sequelae - During initiation and after titration monitor patients to assess serum sodium concentrations and neurologic status. Subjects with SIADH or very low baseline serum sodium concentrations may be at greater risk for too-rapid correction of serum sodium. In patients receiving SAMSCA who develop too rapid a rise in serum sodium, discontinue or interrupt treatment with SAMSCA and consider administration of hypotonic fluid. Fluid restriction during the first 24 hours with SAMSCA may increase the likelihood of overly-rapid correction of serum sodium, and should generally be avoided.

  • Gastrointestinal Bleeding in Patients with Cirrhosis - Used only when the need to treat outweighs this risk

  • Dehydration and Hypovolemia - In patients who develop medically significant signs or symptoms of hypovolemia, discontinuation is recommended. Dehydration and hypovolemia can occur, especially in potentially volume-depleted patients receiving diuretics or those who are fluid restricted.
  • Co-administration with Hypertonic Saline - Not recommended
  • Other Drugs Affecting Exposure to SAMSCA -
    • CYP 3A Inhibitors - Do not use with strong inhibitors of CYP 3A; avoid concomitant use with moderate CYP 3A inhibitors
    • CYP 3A Inducers - Avoid concomitant use with CYP 3A inducers. If co-administered, the dose of SAMSCA may need to be increased
    • P-gp Inhibitors - The dose of SAMSCA may have to be reduced if co-administered with P-gp inhibitors


    '/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 After the holiday season, many ... fitness and exercise. Community Health Center of Snohomish County ... ways that families in Everett, Marysville, and the entire ... , CHC says, “While it’s relatively simple to ... veggies, many families wonder how to keep exercise fun ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 The ... which covers some great ideas when planning an Eco-vacation. ... with an environmentally friendly approach. The segment will explore ... a hotel or resort’s sustainability policy, request Earth-friendly choices ... also remind viewers about how to save electricity while ...
(Date:3/3/2015)... Sponsors of Medicare Advantage (MA) plans ... significant proposed changes to sift through as a result ... Letter released Feb. 20. The potential pay changes alone ... with the type and location of the plan’s membership. ... on them before CMS issues the final notice and ...
(Date:3/3/2015)... March 03, 2015 Dr. Stephen ... Wilmington, NC has achieved Accredited Member Status ... , He achieved this accomplishment after completing a ... as well as the submission of clinical cases ... Wilmington, NC grew up in Connecticut, Charlotte, North ...
(Date:3/3/2015)... UT (PRWEB) March 03, 2015 ... innovative, user-friendly website that focuses on providing an ... boarding schools, and addiction treatment for clients ranging ... residential interventions on the site have a wide ... autism spectrum disorders, severe learning disabilities, drug rehabilitation, ...
Breaking Medicine News(10 mins):Health News:6 Wintertime Weight Loss Tips for Family Fitness Presented by Community Health Center of Snohomish County in Recent Article 2Health News:Forbes Living Segment on Planning an Eco-Vacation in the Works 2Health News:March 12 Webinar to Analyze Implications of CMS’s ’45-Day Notice’ and 2016 Call Letter for MA and Part D Plans 2Health News:Dr. Edgerton, a Dentist in Wilmington, NC, Achieves Accredited Status in AACD 2Health News:All Kinds of Therapy – New Website for Behavioral Health and Substance Abuse Treatment Launches Today 2
... new programme has been initiated to by the government to ... cervical cancer. The Joint Committee on Vaccination and Immunisation want ... done for secondary school first year. And there is expected ... 16. ,The vaccines Gardasil and Cervarix have been ...
... more likely than women to sustain severe human bite injuries ... published in the July issue of the Emergency Medicine Journal ... brawls at weekends or public holidays and in most cases ... patients requiring assessment for human bite wounds by the plastic ...
... group of Filipino women exposed themselves outside the Supreme ... formula companies launched a legal challenge against advertising restrictions ... and 72, said they had all raised healthy children ... reveal hand-painted slogans across their breasts. ...
... A three member-team of the National Commission for Women (NCW) ... today to investigate the unearthing of a large number of ... authorities to get first hand information of the case and ... told reporters that they felt the need to seek first ...
... have invented a device that mimics the naturally disinfecting ... of reactive hydrogen radicals into the atmosphere , killing ... Disinfector can be used to purge hospital wards of ... simply by opening all the windows of hospital wards, ...
... Actress Sharon Stone and other star are heading for Dubai ... the project amfAR hopes top raise maximum money from the ... for its discrimination towards HIV patients, as well as gay ... US state department, 'government officials discriminated against prisoners with HIV ...
Cached Medicine News:Health News:Cervical Cancer Vaccine for the 12 Year Old 2Health News:Filipino Mothers Go Bare Protesting Against Milk Formula Companies 2Health News:New Device Developed to Eliminate Superbugs Within Minutes 2
(Date:3/2/2015)... , March 2, 2015  DURECT Corporation ... Epigenomic Regulator Program, and the successful completion of ... lead product candidate DUR-928.  DUR-928 is an endogenous, ... broad applicability in metabolic diseases such as nonalcoholic ... and in acute organ injuries such as acute ...
(Date:3/2/2015)... -- Intrexon Corporation (NYSE: XON ), a ... quarter and full year results for 2014.  ... , Acquired ActoGeniX, a European clinical stage biopharmaceutical ... and other innovative products.  Its proprietary TopAct™ platform ... Lactococcus lactis ) to generate biologically-contained ActoBiotics™ for ...
(Date:3/2/2015)... SAN DIEGO, March 2, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... fourth quarter and full year ended December 31, 2014. Financial ... and a net loss of $5.3 million, or $0.04 per ... net loss of $22.0 million, or $0.19 per share, for ... year 2014 include revenues of $75.3 million and a net ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
... CHARLOTTE, N.C., July 25, 2011 A leading international ... patients to ask their dentists about the potential for ... and holders that fasten patients, protective bibs in place. ... Research by Dr. John Molinari, Director of Infection Control ...
... In a comparative pharmacokinetic (PK) study, Upsher-Smith ... topiramate in development for the management of epilepsy ... twice-daily immediate-release topiramate (Topamax®*) in its extent of ... demonstrated a slower absorption profile compared with Topamax®. ...
Cached Medicine Technology:Question Your Dentist About Potential for Cross-Contamination, Leading Infection-Control Scientist Tells Fox News 2PK Study Comparing Upsher-Smith's Extended-Release Topiramate Formulation (USL255) With Topamax® Published Online In Epilepsia 2PK Study Comparing Upsher-Smith's Extended-Release Topiramate Formulation (USL255) With Topamax® Published Online In Epilepsia 3
... UltraFix MiniMite Suture Anchor System ... the market that will accept ... surface until deployed eliminates tissue, ... its ultra smooth eyelet hole ...
... The R-F10 simplifies the ... unprecedented degree - all operations ... a press of the Start ... the entire series of steps ...
... imaging have become more acute. The ... radiation exposure to both patient and staff ... and Bi-Plane systems. In keeping with ... in price/value relationship, four bi-plane imaging configurations ...
... HARMONY Cardiology Module incorporates an integrated ... Open Systems Technology mandated by the ... Allowing for easy access to hospital ... HARMONY provides new efficiency with electronic ...
Medicine Products: